Research Analysts Set Expectations for LEXX Q2 Earnings

Lexaria Bioscience Corp. (NASDAQ:LEXX) – Analysts at Zacks Research issued their Q2 2026 earnings per share estimates for Lexaria Bioscience in a note issued to investors on Tuesday, February 10th. Zacks Research analyst J. Vandermosten forecasts that the company will post earnings per share of ($0.07) for the quarter. The consensus estimate for Lexaria Bioscience’s current full-year earnings is ($0.59) per share. Zacks Research also issued estimates for Lexaria Bioscience’s Q3 2026 earnings at ($0.06) EPS, Q4 2026 earnings at ($0.06) EPS, FY2026 earnings at ($0.26) EPS and FY2027 earnings at ($0.31) EPS.

Lexaria Bioscience (NASDAQ:LEXX) last announced its quarterly earnings data on Tuesday, January 13th. The company reported ($0.07) EPS for the quarter, topping analysts’ consensus estimates of ($0.13) by $0.06. The company had revenue of $0.19 million during the quarter, compared to the consensus estimate of $0.14 million. Lexaria Bioscience had a negative net margin of 1,685.84% and a negative return on equity of 226.58%.

A number of other brokerages have also weighed in on LEXX. Wall Street Zen lowered Lexaria Bioscience from a “hold” rating to a “sell” rating in a report on Sunday, December 7th. HC Wainwright reduced their price target on Lexaria Bioscience from $4.00 to $1.50 and set a “buy” rating for the company in a report on Friday, December 26th. Finally, Weiss Ratings restated a “sell (e+)” rating on shares of Lexaria Bioscience in a research note on Monday, December 29th. One analyst has rated the stock with a Buy rating and one has issued a Sell rating to the company. Based on data from MarketBeat, Lexaria Bioscience has an average rating of “Hold” and a consensus price target of $1.50.

Lexaria Bioscience Stock Down 2.7%

Shares of Lexaria Bioscience stock opened at $0.62 on Thursday. The firm has a market cap of $15.44 million, a price-to-earnings ratio of -1.11 and a beta of 0.56. Lexaria Bioscience has a 52-week low of $0.46 and a 52-week high of $1.90. The company’s 50-day simple moving average is $0.76 and its 200-day simple moving average is $0.91.

Institutional Investors Weigh In On Lexaria Bioscience

A number of large investors have recently added to or reduced their stakes in the business. Virtu Financial LLC purchased a new position in Lexaria Bioscience during the 3rd quarter valued at about $28,000. Byrne Asset Management LLC grew its position in shares of Lexaria Bioscience by 236.8% in the fourth quarter. Byrne Asset Management LLC now owns 105,500 shares of the company’s stock valued at $65,000 after purchasing an additional 74,180 shares during the last quarter. Finally, Geode Capital Management LLC increased its stake in shares of Lexaria Bioscience by 25.7% during the 4th quarter. Geode Capital Management LLC now owns 219,718 shares of the company’s stock worth $136,000 after purchasing an additional 44,939 shares in the last quarter. 13.06% of the stock is owned by institutional investors and hedge funds.

About Lexaria Bioscience

Lexaria Bioscience Corp. (NASDAQ: LEXX) is a biotech company specializing in the development and commercialization of proprietary drug delivery platforms. The company’s flagship technology, DehydraTECH, is designed to improve the oral bioavailability, onset time and overall efficiency of active molecules such as cannabinoids, nicotine and other lipophilic compounds. Lexaria’s platform seeks to address absorption challenges commonly associated with oral delivery by enhancing the rate and extent at which compounds enter the bloodstream.

Founded in 2014 and headquartered in Kelowna, British Columbia, Lexaria operates in the pharmaceutical, nutraceutical and consumer product markets.